LENVIMA is indicated in combination with everolimus, for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy.
LENVIMA: Efficacy that drives results1
-
14.6-month median PFS (95% CI: 5.9-20.1) with LENVIMA + everolimus vs 5.5 months (95% CI: 3.5-7.1) with everolimus alone (HR: 0.37 [95% CI: 0.22-0.62]); major efficacy endpoint1
- Number of events: 26 events (51%) with LENVIMA + everolimus vs 37 events (74%) with everolimus alone
PFS=progression-free survival; HR=hazard ratio; CI=confidence interval; aRCC=advanced renal cell carcinoma; AR=adverse reaction; MOA=mechanism of action.
Not an actual patient